arXiv subjects

Cheng-Han Yang

Publications and source records attributed to Cheng-Han Yang.

4 recordsLinked to original sources

arXiv2026

Prediction-based Inference in Electronic Health Record (EHR)-linked Biobanks with Clinically Informative Outcomes

Electronic health record (EHR)-linked biobank data hold tremendous promise for large-scale discoveries via genome-wide association study (GWAS) on diverse phenotypic traits and biomarkers routinely captured in the EHR. However, heterogeneous missingness in biomarkers compromises the validity and efficiency of statistical analyses. Prediction-based (PB) inference methods meet this challenge by using external machine learning (ML) predictions to impute missing biomarker outcomes, thereby improving statistical power and estimation accuracy in association analyses. Yet, their suitability remains unclear when outcomes are subject to clinically informative observation processes, that is, when laboratory tests are ordered based on both measured and unmeasured patient- and health system-level characteristics. In this paper, we review the statistical underpinnings of popular PB methods and then evaluate nine methods, including four PB methods and five traditional missing-data approaches, under an encompassing set of outcome observation processes for continuous and binary outcomes. PB methods can substantially improve statistical power and estimation efficiency when the missing-data mechanism is correctly specified. Under misspecification, however, these gains require both conditional independence between the covariates of interest and the missingness mechanism and independence between imputation error and the missingness mechanism. Using All of Us (AoU) data, we perform GWAS of six laboratory biomarkers and demonstrate that PB methods can replicate known genetic associations while improving efficiency relative to (weighted) complete-case analysis (CCA). Their performance in replicating existing GWAS results in AoU also depends on imputation quality and the underlying missingness mechanism.

stat.AP↗

arXiv2026

Joint Modeling of Longitudinal EHR Data with Shared Random Effects for Informative Visiting and Observation Processes

Longitudinal electronic health record (EHR) data offer opportunities to study biomarker trajectories; however, association estimates-the primary inferential target-from standard models designed for regular observation times may be biased by a two-stage hierarchical missingness mechanism. The first stage is the visiting process (informative presence), where encounters occur at irregular times driven by patient health status; the second is the observation process (informative observation), where biomarkers are selectively measured during visits. To address these mechanisms, we propose a unified semiparametric joint modeling framework that simultaneously characterizes the visiting, biomarker observation, and longitudinal outcome processes. Central to this framework is a shared subject-specific Gaussian latent variable that captures unmeasured frailty and induces dependence across all components. We develop a three-stage estimation procedure and establish the consistency and asymptotic normality of our estimators. We also introduce a sequential procedure that imputes missing biomarkers prior to adjusting for irregular visiting and examine its performance. Simulation results demonstrate that our method yields unbiased estimates under this mechanism, whereas existing approaches can be substantially biased; notably, methods adjusting only for irregular visiting may exhibit even greater bias than those ignoring both mechanisms. We apply our framework to data from the All of Us Research Program to investigate associations between neighborhood-level socioeconomic status indicators and six blood-based biomarker trajectories, providing a robust tool for outpatient settings where irregular monitoring and selective measurement are prevalent.

stat.ME↗

arXiv2025

Meta-analysis of median survival times with inverse-variance weighting

We consider the problem of meta-analyzing outcome measures based on median survival times. Primary studies with time-to-event outcomes often report estimates of median survival times and confidence intervals based on the Kaplan-Meier estimator. However, outcome measures based on median survival are rarely meta-analyzed, as standard inverse-variance weighted methods require within-study standard errors that are typically not reported. In this article, we consider an inverse-variance weighted approach to meta-analyze median survival times that estimates the within-study standard errors from the reported confidence intervals. We show that this method consistently estimates the standard error of median survival when applied to confidence intervals constructed by the Brookmeyer-Crowley method. We conduct a series of simulation studies evaluating the performance of this approach at the study level (i.e., for estimating the standard error of median survival) and the meta-analytic level (i.e., for estimating the pooled median, difference of medians, and ratio of medians) for commonly used confidence intervals for median survival, including the Brookmeyer-Crowley method and nonparametric bootstrap. We find that this approach often performs comparably to a benchmark approach that uses the true within-study standard errors for meta-analyzing median-based outcome measures when within-study sample sizes are moderately large (e.g., above 50). However, when the effective sample sizes are small, the method can yield biased estimates of within-study standard errors. We illustrate an application of this approach in a meta-analysis evaluating survival benefits of being assigned to experimental arms versus comparator arms in randomized trials for non-small cell lung cancer therapies.

stat.ME↗

arXiv2024

DEMO: Dose Exploration, Monitoring, and Optimization Using a Biological Mediator for Clinical Outcomes

Phase 1-2 designs provide a methodological advance over phase 1 designs for dose finding by using both clinical response and toxicity. A phase 1-2 trial still may fail to select a truly optimal dose. because early response is not a perfect surrogate for long term therapeutic success. To address this problem, a generalized phase 1-2 design first uses a phase 1-2 design's components to identify a set of candidate doses, adaptively randomizes patients among the candidates, and after longer follow up selects a dose to maximize long-term success rate. In this paper, we extend this paradigm by proposing a design that exploits an early treatment-related, real-valued biological outcome, such as pharmacodynamic activity or an immunological effect, that may act as a mediator between dose and clinical outcomes, including tumor response, toxicity, and survival time. We assume multivariate dose-outcome models that include effects appearing in causal pathways from dose to the clinical outcomes. Bayesian model selection is used to identify and eliminate biologically inactive doses. At the end of the trial, a therapeutically optimal dose is chosen from the set of doses that are acceptably safe, clinically effective, and biologically active to maximize restricted mean survival time. Results of a simulation study show that the proposed design may provide substantial improvements over designs that ignore the biological variable.

stat.AP↗